Decentralised, point-of-care CAR-T for multiple myeloma
- PMID: 37414061
- DOI: 10.1016/S1470-2045(23)00269-3
Decentralised, point-of-care CAR-T for multiple myeloma
Conflict of interest statement
SA reports a research grant from Janssen; consulting fees from Bristol Myers Squibb/Celgene, Galapagos, Gilead, and Janssen; honoraria including lecture fees from Galapagos, Janssen, and Takeda; travel support from Galapagos, Gilead, Janssen, and Novartis; and participated on advisory boards organised by Bristol Myers Squibb/Celgene, Galapagos, and Janssen. SA also serves as principal investigator on Janssen's CARTITUDE trials with ciltacabtagene autoleucel and on the CellPoint/Galapagos PAPILIO-1 study (EudraCT 2022-500782-27-00). LK reports travel support from AbbVie.
Comment on
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
